Below is a listing of scientific publications and presentations related to Idenix hepatitis C drug candidates.
"Persistence of Resistance-Associated Variants in Hepatitis C Virus (HCV) Genotype 1-4 Infected Subjects Following 3-day Samatasvir Monotherapy
"A Phase II Study of Samatasvir (IDX719) in Combination with Simeprevir and Ribavirin in Treatment-Naïve HCV-Infected Subjects with Genotypes 1b and 4 (HELIX-1 Study)"
"Pharmacokinetic (PK) Drug-Drug Interaction between Samatasvir (IDX719), a Pan-Genotypic NS5A Inhibitor, and Simeprevirin Healthy Volunteers and HCV-Infected Subjects"
"Pharmacokinetics and Pharmacodynamics of IDX719, a Pan-Genotypic HCV NS5A Inhibitor in Genotype 1, 2, 3 and 4 HCV-infected Subjects" , 6.6.2013
"Hepatitis C Virus NS5A Inhibitor IDX719 Demonstrates Potent, Pan-Genotypic Activity in Preclinical and Clinical Studies"
"IDX719, a Pan-Genotypic HCV NS5A Replication Complex Inhibitor, is a Promising Candidate for HCV Combination DAA Treatment"
"Next generation HCV NS5A inhibitor: In vitro antiviral optimization for pan-genotypic activity and preclinical profile"
"Treatment-Emergent Variants Following 3 Days Of Monotherapy With IDX719, A Potent, Pan-Genotypic NS5A Inhibitor, In Subjects Infected With HCV Genotypes 1-4"
"IDX719, HCV NS5A Inhibitor, Demonstrates Pan-Genotypic Activity after Three Days of Monotherapy in Genotype 1, 2, 3 or 4 HCV-Infected Subjects"
"Safety, Pharmacokinetic and Antiviral Activity Results from a First-in-Human Study of IDX719, A Pan-Genotypic HCV NS5A Inhibitor"
"The preclinical profile of the pan-genotypic HCV NS5A inhibitor IDX719 demonstrates its potential for combination therapy"
"Safety, Pharmacokinetic and Preliminary Antiviral Activity Results from a First-in-Human Study of IDX719, a Pan-Genotypic Novel HCV NS5A Inhibitor"
"Combination DAA Strategies to Cure HCV"
"Antiviral and Preclinical Profiles of HCV NS5A Inhibitors IDX380 and IDX719"
"Idenix NS5A HCV replication inhibitors with low picomolar, pan-genotypic in vitro antiviral activity"
"Pharmacokinetics and Safety of IDX21437, a Novel HCV Nucleotide Prodrug, in Healthy Volunteers and HCV-Infected Subjects: Results of a First-In-Human Study"
"Favorable Preclinical Profile of IDX21437, a Novel Uridine Nucleotide Prodrug, for Use in a Direct-Acting Antiviral (DAA) Regimen for HCV"
"A Novel Uridine Nucleotide Prodrug, IDX20963, and Its Potential for Use in a Low-Dose Direct-Acting Antiviral Regimen for HCV"
"Combination DAA Therapy for Hepatitis C"
"Challenges in Designing Trials for Direct Acting Antiviral (DAA) Combination Therapy of HCV Infection Douglas Mayers, Victor De Gruttola 4.30.10"
"Triple Combinations of Direct-Acting Antiviral Agents Demonstrate Robust Anti-HCV Activity In Vitro”